The currently authorized 50-µg booster of Moderna’s COVID-19 vaccine (mRNA-1273) increased neutralizing antibody levels against Omicron approximately 37-fold, compared to two-shot levels, and a 100-µg dose of the vaccine increased neutralizing antibody levels approximately 83-fold, compared to two-shot levels, Moderna said in a news release, citing preliminary data about neutralizing antibodies.
The data described in the news release “includes sera from 20 booster recipients each of mRNA-1273 at the 50-µg and 100-µg dose levels, multivalent candidate mRNA-1273.211 at the 50-µg and 100-µg dose levels, and multivalent candidate mRNA-1273.213 at the 100-µg dose level,” Moderna said.
The neutralizing antibodies against Omicron were analyzed using a pseudovirus neutralization titer (PsVNT) (ID50) assay. A preprint submission is being prepared based on the data.
Separately, the company also announced the safety and tolerability data from the Phase 2/3 study of the 100-µg booster dose of mRNA-1273. “A 100-µg booster dose of mRNA-1273 was generally safe and well tolerated. The frequency and nature of solicited systemic and local adverse events 7 days after receiving a booster were generally comparable to those seen after the two-dose primary series. There was a trend toward slightly more frequent adverse reactions following the 100-µg booster dose relative to the authorized 50-µg booster dose of mRNA-1273,” Moderna said.
